Answers are grounded in this paper and cite their sources.
Objectives Monitoring of opioid prescribing using Average Daily Quantities or Daily Defined Doses has limitations. The aim of this work was to establish oral morphine equivalence for opioid products, which could be used as a unit of measure to monitor the opioid National Prescribing Indicator in Wales, and to assess its impact on primary care prescribing data. Methods Oral Morphine Equivalence for each opioid product dispensed in Wales was calculated based on available reference sources. The impact on opioid prescribing ranking of the seven health boards and 370 General Practices in Wales, as well as on the proportional prescribing of opioid medicines underpinning any differences, was assessed using routinely collected, anonymized, secondary dispensing data. Key findings Prescribing ranking of six health boards and over 97% of General Practices changed using Oral Morphine Equivalence compared with either Average Daily Quantity or Defined Daily Dose. On average across health boards, percentage contribution of co-codamol (all product strengths combined) to total opioid prescribing varied most according to the measure used, accounting for 55% of Average Daily Quantities, 12% of Defined Daily Doses and 33% of Oral Morphine Equivalence. Conclusions Introduction of the Oral Morphine Equivalence measure impacted the prescribing ranking of health boards and general practices, with possible implications for implementation of prescribing incentive schemes. Co-codamol prescribing was most impacted by changing the prescribing measure, and the contribution of this drug to total prescribing and associated adverse events warrants further investigation.
No takes yet. Share an insight, caveat, or question.
Gill et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: